Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.
Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Ecstein E, Untereiner M, Vuillemin E, Merran S, Andrieu JM. Tourani JM, et al. Among authors: pavlovitch jm. Ann Oncol. 1996 Jul;7(5):525-8. doi: 10.1093/oxfordjournals.annonc.a010644. Ann Oncol. 1996. PMID: 8839910 Free article. Clinical Trial.
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM, Jaillon-Abraham C, Lucas V, Chrétien Y, Mayeur D, Di Palma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Larregain D, Ecstein E, Untereiner M, Andrieu JM. Tourani JM, et al. Among authors: pavlovitch jm. Bull Cancer. 1997 Apr;84(4):351-6. Bull Cancer. 1997. PMID: 9238157 Free article. Clinical Trial. French.
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C. Tourani JM, et al. Among authors: pavlovitch jm. J Clin Oncol. 1998 Jul;16(7):2505-13. doi: 10.1200/JCO.1998.16.7.2505. J Clin Oncol. 1998. PMID: 9667271 Clinical Trial.
Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
Tourani JM, Grise P, Lucas V, Mayeur D, Dufour B, Di Palma M, Boaziz C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Untereiner M. Tourani JM, et al. Among authors: pavlovitch jm. Cancer Biother Radiopharm. 1996 Oct;11(5):297-300. doi: 10.1089/cbr.1996.11.297. Cancer Biother Radiopharm. 1996. PMID: 10851507 Clinical Trial. No abstract available.
External irradiation prior to conservative surgery for breast cancer treatment.
Calitchi E, Otmezguine Y, Feuilhade F, Piedbois P, Pavlovitch JM, Brun B, Mazeron JJ, Le Bourgeois JP, Julien M, Pierquin B. Calitchi E, et al. Among authors: pavlovitch jm. Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):325-9. doi: 10.1016/0360-3016(91)90778-3. Int J Radiat Oncol Biol Phys. 1991. PMID: 1648043
[Consensus and controversies in conservative treatment indications].
Calitchi E, Otmezguine Y, Feuilhade F, Brun B, Pavlovitch JM, Piedbois P, Mazeron JJ, Julien M, Baruch J, Le Bourgeois JP, et al. Calitchi E, et al. Among authors: pavlovitch jm. Pathol Biol (Paris). 1990 Oct;38(8):839-40. Pathol Biol (Paris). 1990. PMID: 2274379 French. No abstract available.
[Arterial stenosis after radiotherapy].
Piedbois P, Becquemin JP, Pierquin B, Blanc I, Mazeron JJ, Pavlovitch JM, Otmezguine Y, Calitchi E, Brun B, Feuilhade F, et al. Piedbois P, et al. Among authors: pavlovitch jm. Bull Cancer Radiother. 1990;77(1):3-13. Bull Cancer Radiother. 1990. PMID: 8703540 Review. French.
19 results